RetinaLyze prevents vision loss

RetinaLyze is an effective visual health service that works tirelessly to prevent the threatening blindness of people around the world.

It is a software, which, through a vectorial algorithm, detects, in premature stages, indications of small lesions, which could in future cause loss of vision, due to diabetic retinopathy or due to age-related macular degeneration, from a photograph of the eye fundus (made with a Retinograph).



Danish Multinational Novo Nordisk A / S, one of the world’s leading manufacturers of insulin, one day raised the challenge of investigating how to prevent the threatening blindness of people with diabetes. To do this, they began to develop software in which a vectorial algorithm, based on a photograph of the ocular fund, made with a Retinograph, detects, in premature stages, indications of small lesions, which could in the future cause the loss of view.

In 2008, the crisis forced to stop the research and implementation, until Jens Thygesen, one of the ophthalmologists who participated in the creation of the software bought it and began using it in his hospital in Copenhagen.

In 2014, the analytical method was exported to the cloud and made accessible trough internet. Since its appearance in the market, RetinaLyze has quadrupled its profit. With a global expansion, it operates in Europe, the United States, China, Japan, India, Australia, among others. In China there are already 7000 public hospitals that use this method.

From Bolivia the expansion to Argentina, Brazil, Chile, Colombia, Uruguay and Peru begins, totalizing 7 countries for which we have the representation.


Fight against preventable blindness

In the world there are 50 million blind people and 250 million with very limited vision. These figures will double by 2020 unless we do something.

Meanwhile, diabetes is a disease that is progressing worldwide and it is estimated that by 2020 there will be more than 300 million registered diabetics (type 1 or 2). Besides, by that time it is estimated that the number of unregistered diabetics will exceed 250 million, being one of the most feared consequences of diabetes, diabetic retinal pathology, as it can lead to blindness.

It is estimated that 90% of blind people live in developing countries and that 90% of these cases are treatable and avoidable at very low cost using appropriate technology.

RetinaLyze is an important ally in the fight against blindness, since it allows an early diagnosis, using latest technology through an effective, fast and reliable method.

Identify at an early stage the risk of blindness due to diabetic retinopathy or age-related macular degeneration.
Develop prevention strategies against blindness, with doctors, government organizations, institutions and public and private companies.
Provide a rapid, flexible and effective service at an affordable price to the entire population of Bolivia and the World.


Facilitate visual examination to prevent dramatic consequences of delayed treatment of retinal lesions by working closely with doctors, ophthalmologists, clinics and hospitals through an effective, rapid and reliable method.


Being a reference of fight in Bolivia and the world to prevent and reduce rates of people’s blindness, improving the quality of life of those who might be affected.

Presentation of Retinalyze Bolivia

RetinaLyze allows you to provide an excellent visual health service.